Digital pathology expansion Acupath has recently integrated with Artera to send biopsy slide images and receive results within 24 hours, signaling a strategic push toward faster digital workflows that can be leveraged to cross-sell advanced imaging, AI-assisted analysis, and downstream informatics services.

Strategic tech partnerships Recent collaborations with Azer Scientific for the first AzerView Digital Pathology scanner in the United States and with Lumea for digital pathology viewing indicate a strong openness to adopting cutting-edge diagnostic platforms, presenting opportunities to offer complementary hardware, software, and implementation services.

Comprehensive test menu With a broad specialty focus across urology, GI, hematology/oncology, dermatology, breast, gynecology, ENT, podiatry, and oral, Acupath serves well over 500 active clients and processes over 150,000 specimens annually, creating a wide potential for bundled test panels, extended service lines, and targeted outreach to high-volume referrals.

Evidence-driven value The company has published white papers and has a track record of internal studies on biomarkers such as URO17, underscoring a commitment to evidence-based diagnostics that can be leveraged to position additional molecular assays, companion diagnostics collaborations, and payer-focused value propositions.

Growing digital reach Sustainability of growth is suggested by ongoing digital and cloud-based tech stack adoption (Azure, SQL Server, SAP, Shopify, Google Ads) which indicates receptiveness to modern sales enablement, CRM integrations, and data-driven campaigns to drive client acquisition and upsell of high-margin services.